Showing 1-10 of 12 "Transplant Trials"

Status: Enrolling

Investigator: Arvind Bhimaraj

Study Coordinator: Colleen Brown

Phone: 713.441.3576

The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance ... Read more >

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Joel Cisneros

Phone: 713.441.6311

The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also e ... Read more >

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Joel Cisneros

Phone: 713.441.6311

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant. ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Joy Nolte

Phone: 713.441.6314

BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents used to lower acute rejection rat ... Read more >

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Susan Dorman

Phone: 713.441.6316

The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant. ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Joel Cisneros

Phone: 713.441.6311

The purpose of this treatment registry study is to determine if monthly infusions of Intravenous Immunoglobulin (IVIg) for 6 months will neutralize donor specific antibodies that are thought to be responsible for chronic rejection episodes in re ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Joy Nolte

Phone: 713.441.6314

The purpose of this study is to determine if Eculizumab is safe and could be used to prevent delayed graft function following kidney transplantation. ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >

Status: Open Not Enrolling

Investigator: Jean Bismuth

Study Coordinator: Kim Donlon

Phone: 713.441.9394

The purpose of this post-approval study is to evaluate the long-term performance of the GORE TAG® Thoracic Endoprosthesis (TAG device) in the primary treatment of descending thoracic aortic (DTA) aneurysms ... Read more >

Status: Enrolling

Investigator: Patrick Reardon

Study Coordinator: Yarley Perry

Phone: 713.796.0500ext134

To compare mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD). ... Read more >

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Joy Nolte

Phone: 713.441.6314

This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients. ... Read more >

Status: Open Not Enrolling

Investigator: Jerry Estep

Study Coordinator: Arati Bhosale

Phone: 713.441.3910

This study will investigate the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg tafamidis meglumine soft gel capsules in comparison to placebo and given once daily, in addition to standard of care, for 30 months in subjects ... Read more >